|
Post by gomnkd on Apr 9, 2015 9:10:17 GMT -5
I think @davinci hit the nail on its head. It is not about stock price at the moment, but the fundamentals. I've held on to stocks that have dropped 50% from where I bought and made money and some that I've lost 95% and never recovered from fundamental/stock point of view.
The question is about sales/marketing strategy and execution. I'm wondering why they couldn't get any mainstream media outlets to talk about it? why not a plug in cnn, abc..? I've heard (from cafepharma) that Sanofi screwed up Apidra, their market share certainly proves it. I would have questioned these even when stock is at 10. Sooner or later fundamentals will catch up to stock price. I think the market is giving us a lot of latitude, if not we would be trading lot lower. If you want to build awareness to endos/pcp first, why not an ad in NEJM, journal of internal medicine, or other diabetes trade publications?
Except for Al Mann, other MNKD insiders are selling stock faster than an anorexic girl eating chocolates after knowing Armageddon is coming. MNKD shareholders have 2.6 billion reasons to question their strategy. This ain't FUD. My ideal situation is when stock is languishing at $5 and sales growing rapidly.
Ok, my venting is now over.
|
|
|
Post by kball on Apr 9, 2015 9:19:58 GMT -5
In his defense I don't think he's saying Exubera is the same as Afrezza. He was pretty careful to say he knew Afrezza was better. The problem is do OTHER people know that it's better? That's the billion dollar question. Unfortunately, perception is often reality. Interesting data point that Sam and Eric both started on (and had access to) Afrezza before official launch 2/3. Clearly these 2 chaps are leading the parade. Still hoping for some celebrity exposure in upcoming tv ads whenever they debut. Spiro with the coolest pic of them all imo. (new tagline...suck on this!)
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 9, 2015 10:32:25 GMT -5
Several, many posts taking the conversation away from my points towards dead ends such as: 1. why don't you just sell and move on? ANSWER - Because this is an investment that I'm in the middle of and I haven't made the decision on whether I'm going to hold or liquidate some or all of my position, or, add to it. I'm always in information gathering mode and don't shut off just because I made a decision to buy into a position. 2. Still too early in the game. If TRx growth is slow come late October, I would push the panic button. RESPONSE - one lesson I've learned about investing is that you want to be first into the room and the first to leave. I'm ok if nobody agrees with me on that point (or any point frankly) but that's just what I've come to learn as an essential part of successful investing, and I've been successful. 3. So you're saying that all the early users of Exubera raved about how fast it worked, how well they were able to control their BG, how easy it was to use, etc. etc.? ANSWER - yes to the idea that there were rabid exubera users, no to the correlations between what exubera users liked vs what afrezza users like. I would also add that I do NOT believe afrezza is exubera nor do I believe that afrezza should fail on any level. But many who read my posts won't digest that info because it doesn't fit in with their narrative. I look at ALL sides of the picture, not just what makes me warm and fuzzy 4. Knowing you are dissatisfied; it's clear MNKD is not the right investment for you. RESPONSE - lol......that was worth a laugh. 5. One big difference in my opinion (all technical aspects aside) is today's social media. RESPONSE - I agree. 6. Thanks for your independent thinking. RESPONSE - thanks for accepting uncomfortable ideas. It always serves to keep me honest in my investment thinking. 7. and he's making a lot of assumptions to make correlations that Afrezza is taking the same path as Exebura did. RESPONSE - what assumptions? What I've stated is what was done with exubera and what is going on right now with afrezza. I haven't reaching into the future or rewrote history. This is happening right now, so not sure about what I've assumed? 8. Can you provide any proof to anything you posted. RESPONSE - oh...my....goodness.......if a person has invested in MNKD but doesn't know the details of exubera, pfizer, sanofi and how all that went down including the post mortem analysis that was abundant from 2007 onward, then you're missing a serious part of your DD on afrezza imho. Asking for proof about what happened to exubera is like asking for proof that the oceans are full of water - simply go take a look and, in this example, do some reading.
|
|
|
Post by kball on Apr 9, 2015 10:48:07 GMT -5
Interesting data point that Sam and Eric both started on (and had access to) Afrezza before official launch 2/3. Clearly these 2 chaps are leading the parade. Still hoping for some celebrity exposure in upcoming tv ads whenever they debut. Spiro with the coolest pic of them all imo. (new tagline...suck on this!)Or maybe even better..."Leave The Prick At Home"
|
|
|
Post by thekindaguyiyam on Apr 9, 2015 11:00:23 GMT -5
Several, many posts taking the conversation away from my points towards dead ends such as: 1. why don't you just sell and move on? ANSWER - Because this is an investment that I'm in the middle of and I haven't made the decision on whether I'm going to hold or liquidate some or all of my position, or, add to it. I'm always in information gathering mode and don't shut off just because I made a decision to buy into a position. 2. Still too early in the game. If TRx growth is slow come late October, I would push the panic button. RESPONSE - one lesson I've learned about investing is that you want to be first into the room and the first to leave. I'm ok if nobody agrees with me on that point (or any point frankly) but that's just what I've come to learn as an essential part of successful investing, and I've been successful. 3. So you're saying that all the early users of Exubera raved about how fast it worked, how well they were able to control their BG, how easy it was to use, etc. etc.? ANSWER - yes to the idea that there were rabid exubera users, no to the correlations between what exubera users liked vs what afrezza users like. I would also add that I do NOT believe afrezza is exubera nor do I believe that afrezza should fail on any level. But many who read my posts won't digest that info because it doesn't fit in with their narrative. I look at ALL sides of the picture, not just what makes me warm and fuzzy 4. Knowing you are dissatisfied; it's clear MNKD is not the right investment for you. RESPONSE - lol......that was worth a laugh. 5. One big difference in my opinion (all technical aspects aside) is today's social media. RESPONSE - Your attitude has changed since yesterday. Yesterday you stated that the comparison was with Exubra. You stated you were disappointed with management, that their was not enough marketing etc. Here you say you laugh when someone who clearly hears your dissatisfaction and uses active listening to reflect your own stated dislike for the way this "revolutionary" medication is being marketed (supply and demand). Today that's laughable to you. Well buddy, let me tell you this. Everyone who knows anything about Afrezza knows that it has no similarity to Exubra from the science medical perspective. The Shorts play the Exubra game continuing for months at a time the same old stuff "with intent" to bring the price down. Why would someone who doesn't like the company or management stay on a board to complain endlessly? Are they humanitarian watching out for other investors warning us of a scam? On and on and on. I always wonder why someone who is investing stays with that investment with the cynicism and criticism you portray as an armchair CEO. Your influence is on the board be it YMB or Proboards. The difference here is that this board is moderated with tolerance for critical voices so there is some balance. Just as other posters have supported or negated my own perceptions; this board is superior for putting up with posters who are either ignorant, entitled, either deliberately leaving out information or looking at the world through blinders. No doubt AF would have appreciated the first post you wrote as it closely resembles to me some of the characteristics of a short who wants to stay on the board for whatever means for attention to drive home points that have been discussed and disputed. Personally; if there were an ignore button on this board I would have used it on you. You will likely reply; "then don't read me". I read as much as I can; even the stuff that has been reiterated. So here we are again... This time, your views are a bit more balanced as you declare your right to hold the shares as a license to challenge those who have brought us to the marketing point (now handled by Sonofi) what has been a 15 year endeavor to treat one of humanities most invasive diseases. There is a lot to Celebrate for those who have Diabetes.... while the other point of view... the stock market view see's it another way... as a commodity which concentrates on conflict regarding daily gains and loses. I interpret your words to reflect the market and not the science. You are addressing, not the general population, but a collective of patients, doctors, and other's personally affected and more knowledgable than most. I see you as a critic who is unhappy with management, marketing and share price. Me. I've bet the farm. Many of us have endured the swings of manipulative practices by the regular suspects and I have little tolerance for more of the same BS coming at me day after day by the same guys who act as if they are humanitarians to share "concern" but aren't smart enough to leave the stock behind to find one that meets their own personal criteria of how the company "should" run based on the limited amount of information available to anyone other than management. But... certainly you have your opinion. Everyone has one; I have one. When I go to movie, a restaurant, read a book, or hang out with people; I have the choice of staying or leaving because I'm not happy with it. You have the same choice. I may be wrong. But I see you as a Short with intention to move the stock your way. FWIW Glad, I'm able to make you laugh... it may bring you up for the lows you feel from the investment YOU made based on Your DD.
|
|
|
Post by jpg on Apr 9, 2015 11:04:23 GMT -5
Maybe looking at this from a different perspective might help? Look at this through the eyes of Sanofi. Sanofi has diabetes sale problems and a very new CEO. Lantus is their big deal in diabetes. A Lantus copy will soon be sold in the US in the not to distant future. Toujeo is now approved but Novo is hot on their heals with Tresiba which will probably be approved this year (in 6 months...). The big question is will Sanofi find Afrezza useful going forward or an obstacle? From my point of view I can't really see how Sanofi would not want Afrezza. Their priority for the next 'x' time will be getting patients to switch to Toujou before Tresiba shows up though. Why would that hurt Afrezzq really? I still see Afrezza being studied with Toujeo going forward and establishing superior control. One thing that scares me would be seeing Sanofi focus more on the bigger type 2 market before addressing the type 1 market well. The 12unit dosing is necessary to dealing with type 2s and should be here 'soon' but I would like to see a 2 unit version under development for the type 1 market. There clearly seems to be a need (real or perceived: I think it is real) for a smaller dosing and not seeing Mannkind and Sanofi move on that would be worrisome to me. The 2 unit version would at least reassure patients and doctors that there is a full range of dosing options. The 2 units might not be used so often but for corrections it seems as if it would be used frequently. How complicated is it getting this past regulators? I don't know. Will Mannkind and Sanofi go that way after the 12 units? Novo's Tresiba news injects uncertainty in insulin market, particularly for Sanofi FDA accepts Tresiba for review just two weeks after its submitted April 8, 2015 | By Eric Palmer www.fiercepharma.com/story/novos-tresiba-news-injects-uncertainty-insulin-market-particularly-sanofi/2015-04-08
|
|
|
Post by liane on Apr 9, 2015 11:06:00 GMT -5
I'm not going to jump into this thread other than to say that any member can block another member. Just click on the member name, then click on the drop-down options (upper right), then "Block member".
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 9, 2015 12:25:28 GMT -5
I'm among the most objective investors that I personally know. I can say that because while I hold my long positions, I continually challenge my long position. I don't do short positions. It doesn't fit with my personality as I don't like to invest hoping for failure. It just doesn't compute for me. But I don't confuse objectivity with bashing or pumping and if my posts annoy you that much, simply follow the good advice by liane and block my posts. However, if you like objectivity, please respond to my posts with your thoughts.
Why do you come on this and other boards like it? I do it to read other perspectives, maybe catch a nugget or link or some other piece I hadn't seen or considered. It helps me to continually round out, challenge, and even modify my investment approach when I deem it right to do so based on the totality of information available. I also have a relatively small group of varied professionals that work together on our spare time to chew over investment ideas. We have varied backgrounds and compliment each others strengths and weaknesses very well. Sometimes, as in the case of MNKD, we'll take on additional efforts as a group to help us fill out our perspectives with as much detail as possible. I attend meetings when I can, I listen to all CCs, I follow the competition, I read all sec docs, and yes - I'm one of the few retailers to actually still look at balance sheets, P&Ls, inventory, etc
So, if that's not your thing, it's ok with me. Maybe just put me on ignore will serve you well and you'll sleep better at night.
As someone pointed out, "yesterday I said this while today you're saying that......." ANSWER - um, yep. What's your point? I live in the grey area since much of the world is not nearly as black and white as many want to believe. I submit that money is made in the grey area. That's true imho because if it was all black and white, it wouldn't be the stock market, it would be a bank CD. I'm comfortable with my risk because I don't sit in the dark hoping it all works out some day.
|
|
|
Post by me on Apr 9, 2015 12:34:44 GMT -5
Several, many posts taking the conversation away from my points towards dead ends such as: 1. why don't you just sell and move on? ANSWER - Because this is an investment that I'm in the middle of and I haven't made the decision on whether I'm going to hold or liquidate some or all of my position, or, add to it. I'm always in information gathering mode and don't shut off just because I made a decision to buy into a position. 2. Still too early in the game. If TRx growth is slow come late October, I would push the panic button. RESPONSE - one lesson I've learned about investing is that you want to be first into the room and the first to leave. I'm ok if nobody agrees with me on that point (or any point frankly) but that's just what I've come to learn as an essential part of successful investing, and I've been successful. 3. So you're saying that all the early users of Exubera raved about how fast it worked, how well they were able to control their BG, how easy it was to use, etc. etc.? ANSWER - yes to the idea that there were rabid exubera users, no to the correlations between what exubera users liked vs what afrezza users like. I would also add that I do NOT believe afrezza is exubera nor do I believe that afrezza should fail on any level. But many who read my posts won't digest that info because it doesn't fit in with their narrative. I look at ALL sides of the picture, not just what makes me warm and fuzzy 4. Knowing you are dissatisfied; it's clear MNKD is not the right investment for you. RESPONSE - lol......that was worth a laugh. 5. One big difference in my opinion (all technical aspects aside) is today's social media. RESPONSE - I agree. 6. Thanks for your independent thinking. RESPONSE - thanks for accepting uncomfortable ideas. It always serves to keep me honest in my investment thinking. 7. and he's making a lot of assumptions to make correlations that Afrezza is taking the same path as Exebura did. RESPONSE - what assumptions? What I've stated is what was done with exubera and what is going on right now with afrezza. I haven't reaching into the future or rewrote history. This is happening right now, so not sure about what I've assumed? 8. Can you provide any proof to anything you posted. RESPONSE - oh...my....goodness.......if a person has invested in MNKD but doesn't know the details of exubera, pfizer, sanofi and how all that went down including the post mortem analysis that was abundant from 2007 onward, then you're missing a serious part of your DD on afrezza imho. Asking for proof about what happened to exubera is like asking for proof that the oceans are full of water - simply go take a look and, in this example, do some reading. OK...so I'll address the points of your original post point-by-point: "...the fact is pretty clear that wall street views afrezza as pretty much identical to exubera." You have no idea the "Wall Street" view of MNKD, because you are not privy to the actual net long position of the shorts out there. 90 million+ shares short, huh? If you think that's the end of the story, you're in a heap of danger. Your "fact," in fact, is pure speculation.
Anything sound familiar so far in terms of how afrezza is going? Lets review. 1. sano is doing a slow controlled launch, just like pfizer did with exubera. Yes, they are. It's a typical approach in the pharma business for about the last 6 to 8 years, given the overcrowding of drug categories. A little research will enlighten you (normally, I'd provide you some links, but just as you previously told others to do their own research, I'll suggest you do the same).2. sano is concerned about having enough supply. Where did anyone at SNY express concern over not having enough of a supply of Afrezza?3. sano is apparently just as confident that afrezza will sell itself based on the playbook they are following so far. Where did anyone at SNY state that Afrezza will sell itself? On the other hand, as an investor, I know I prefer when management is confident in its products.I'm also bothered that MNKD is no longer responsible for sales as that's sano's job now. We've obviously known that reality since the deal was announced but here's my problem - I'm long in MNKD betting on good sales but sales is something that ins't in MNKD's control. Why on earth would you want MNKD to do the selling when they have no sales staff, no national relationships with providers and no prior experience with detailing providers?! Are you hoping for Afrezza to implode? But I view afrezza sales as the future of MNKD. Technosphere isn't producing any income nor is it showing signs that it will anytime soon. Yes, there is no current income for new Technosphere application, but not showing signs to whom? To your privileged self? Have you never run a business before? Do you not understand that you're not going to hear a company's status/plans for a new product at each stage of planning? With MNKD's gag order on discussing T, seems it can be years before we'll hear anything on T. So how do you know the "gag order on T" will delay information for years?! It also "seems" it could be only days. So MNKD is all about sales now but they have no control over sales. So I am questioning what I'm invested in with MNKD? This is obvious to the most casual observer. It also appears that your "history lesson" is a cloaked attempt to get others to question their own investment decisions in MNKD. I also have issue with: 4. Review the initial script numbers. While they are marginally higher - and yes, sales are only marginally higher when you compare what it takes to reach blockbuster status. At this stage the difference in scripts is akin to the difference in the weight of a newborn babies. Nine pounds is percentage wise much bigger than 7 pounds, but, we're still talking small sizes. Same with exubera scripts vs afrezza script counts - same ball park. So, afrezza is NOT taking the market by storm, at least not initially. And you can make this statement because you know precisely there are zero patients using Afrezza samples? And you know the number of Afrezza patients on Medicare, Medicaid and TriCare are zero also? Please enlighten us. 5. Pricing is at a premium for afrezza just like they did for exubera. Pricing relative to Exubera is irrelevant. Pricing is comparable to pens. Alfred said years ago that they learned the exubera lessons - apparently, they did not. Small inhaler, insulin monomer, little titration...Are you really trying to convince us that Al did not learn the lessons of Exubera?! Now we're getting closer to a comedy act.6. Insurance is placing afrezza as tier 3 at best. Today, almost every single new brand name drug starts at Tier 3. That means sano has to provide deep discounts to get the price down to somewhere that a patient will pay for it. You really shouldn't comment on topics you know nothing about. If one has a three-tier prescription copay plan, and one Tier 3 drug costs $10,000 per month and another costs $150 per month, in almost all cases, the patient's out-of-pocket is the same - the copay. Even needle haters will take pause in buying afrezza when they have to reach into their wallets each month to pay significantly more for a medication [wrong, you are really off-base on this - see prior comment] that may or may not cause lung cancer. Guess what, reading your posts may or may not cause lung cancer. Drinking water may or may not cause lung cancer. Breathing may or may not cause lung cancer. The real question is does Afrezza cause lung cancer. So far, the only trial results we have show a reduced incidence of lung cancer among Afrezza users. Does that mean that Afrezza cures lung cancer? If I were as loose with my reasoning as some here, I might say yes it does. YES, I said it. I just said what every competitor is buzzing in the ears of every doc they talk to. 7. Endo's were conservative back in 2006 and it would seem that nothing has changed much. The endo's won't be changing their patients anytime soon in bulk. Do no harm is ruling the day just like it did back in exubera's launch. The endo's are the gate keeper Are you really suggesting that internists, family practice and GPs will not be prescribing this medication? and sano isn't showing any signs that they have the magic formula with afrezza. And finally, the excuses. We're not but 10 weeks into the launch and the excuses why scripts are so anemic are flying already. I'm seeking a link to a SNY executive's (or even a rep's) excuse as to why sales are so pitiful. I still haven't found one. Care to enlighten us? On top of that are the grand statements of success based on a few you tubers. So you make up the story that SNY has a bunch of excuses for a "failed launch," but when actual testimonials of diabetics are in front of you, they're meaningless?! Exubera had the same type of believers as well and that didn't change the course of exubera. When I went back to read posts in the 2005 to 2007 timeframe surrounding NKTR and pfizer it's scary crazy how similiar the posts are to today's rabid afrezza believers. I say it that way because when I step back and take a bigger picture view, that's how it lays out. Current events are beginning to look a lot like exubera history. Well, I sure hope you don't think that my post here, "tak[es] the conversation away from my points towards dead ends," because I addressed your points and your points only.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 9, 2015 12:39:33 GMT -5
me....I think all your points have merit. Thanks for sharing.
|
|
|
Post by thekindaguyiyam on Apr 9, 2015 12:39:35 GMT -5
Your references to Exubra with roll out compared to Afrezza and comments about cancer state exactly where you are at. Have no concerns about how I sleep; as what you have contributed have not changed my opinions at all. Just as your opinions will not change Sonofi's marketing or Alfred Mann's contract with Sonofi based on his lifetime experience and inventions. So be the CEO armchair critic you are and hold stock you aren't sure of. While that may not help you sleep at night; you can draw some confidence by the early results submitted by patients who use the drug and know how it has enhanced their lives. As an investor; you can only hold yourself responsible for the decisions you made by purchasing stock from the existing management. The System will not respond to your Malarkey. Congratulations on letting a little light into your commentary in contrast to the original post you made. Perhaps you might want to read it again.
|
|
|
Post by harryx1 on Apr 9, 2015 13:14:38 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 9, 2015 13:24:04 GMT -5
Your references to Exubra with roll out compared to Afrezza and comments about cancer state exactly where you are at. Have no concerns about how I sleep; as what you have contributed have not changed my opinions at all. Just as your opinions will not change Sonofi's marketing or Alfred Mann's contract with Sonofi based on his lifetime experience and inventions. So be the CEO armchair critic you are and hold stock you aren't sure of. While that may not help you sleep at night; you can draw some confidence by the early results submitted by patients who use the drug and know how it has enhanced their lives. As an investor; you can only hold yourself responsible for the decisions you made by purchasing stock from the existing management. The System will not respond to your Malarkey. Congratulations on letting a little light into your commentary in contrast to the original post you made. Perhaps you might want to read it again. Glad to know. I'm glad your opinion hasn't changed. Does it surprise you that my posts aren't about you and others opinions? I want to hear them if you have something you'd like to point out or share, but, otherwise, the suggestion that I'm sitting here working on my thesis a bit every day actually has something to do with someone else and what they are or aren't doing? Seriously? I do hope you're sleeping well and I do hope you have convictions on your investments. I don't want anyone to trade on my posts much like I wouldn't suggest anyone take action from message boards of any type. It confuses me that many posters dwell in this side of things. Dare I even ask what makes you believe that I or anyone expects the "system" as you put it to respond to me? Baffling to me about what your line of thought is.....but, no matter. My posts are about my investments and not about others and their choices and their investments. I'm discussing what was and what is and where things might be going (good or bad) based on my research. I find patterns and go with it. I take on differing viewpoints and walk a mile in those shoes to see how it fits. I'm confident in my decisions and I can handle challenging my decisions as I go forward. I'm comfortable with my process. But make no mistake, that process of mine has nothing to do with anyone else or dependent on what anyone else thinks or does with their investments. Pure and simple.
|
|
|
Post by jpg on Apr 9, 2015 13:28:22 GMT -5
Hi Davinci, I gave you a thumbs up for your last post because as a stand alone post it has obvious merit. We need different opinions to make better decisions. I have limited (polite) understanding of trading 'tricks and strategies' and the intricacies of contracts for these types of deals so therefore like the input of posters who know more about these things. This being said I find it strange you would be sensitive to comments by others seeing the label you chose for this tread: The parallels to exubera are starting to show! It's actually hard to come up with a more preconceived negative tittle then that. I read it and was going to skip this whole tread because it just seems like a MF or Yahoo type posting. Sadly and as usual I couldn't resist and followed the long rambling conversation (and added a bit to it myself...). I say long and rambling because we all know all these things to be true, potentially true, possibly true, probably not true, possibly false, probably false etc... My point being only time will tell for the vast majority of what you stated and many others are stating. Yes money is made in the grey zone and yes Mannkind has always been in the grey zone. Individuals will look back and say 'but it was so obvious'. What will they say was so obvious will only be obvious at that future time point though... I'm an MD and I evaluate stuff as an MD. The first thing that surprises me after any drug approval is the compression of time in investor vs MD culture. I've only prescribed or given a few drugs immediately after approval: partly by caution and partly by lack of knowledge about various new drugs and the urgency of a better alternative. We don't have time to keep up with what's new let alone what will be coming down the pipeline even if it is revolutionary. We can at best follow stuff from our own field of expertise. I can name you a long list of drugs that were met by cautious or very cautious medical opinions and are now standard of care. With what I know medically about Afrezza I would have no hesitation to say that it is an effective and extremely desirable drug in well selected patients (and that the 'well selected' piece of the pie is huge). Will Sanofi and Mannkind screw it up? Don't know. I can also state that I never expected the innovative ways many of the type 1s who use the drug modify protocol and get very good results. I was expecting a bit of tinkering around the edges but not what they are doing (and remarkably effectively I may add: this seems relatively consistent and ground breaking). Will Mannkind and Sanofi notice and act on it or screw it up? Don't know. If I was a type 1 I would be very interested in quickly trying this. It seems to change not only HbA1C but quality of life dramatically. Other things I do know is well expressed by this simple analysis: blogs.barrons.com/stockstowatchtoday/2015/03/24/mannkind-more-confidence-lower-target/?mod=yahoobarrons&ru=yahooMarch 24, 2015, 9:46 A.M. ET MannKind: More Confidence, Lower Target Email Print smaller Larger By Ben Levisohn Jefferies’ Shaunak Deepak says he is “more confident in the long-term sales potential of [MannKind's (MNKD)] Afrezza” despite lackluster early sales. He explains why: PR Newsfoto/Associated Press We spoke with 16 endocrinologists at the ENDO meeting, none of whom had prescribed Afrezza as of early March. However, feedback suggested strong interest in the drug, so we spoke to two physicians at diabetes centers who had prescribed the drug six and four times, respectively. The first physician had prescribed Afrezza in patients with Type 2 diabetes who were failing basal insulin alone. He suggested that some physicians may see the adoption of mealtime insulin as a logical step before basal insulin, but that the basal-first paradigm was “cast in stone,” suggesting there may be a long learning curve for first-line Afrezza adoption. The second physician described using Afrezza instead of injectable mealtime insulin in both Type 1 and Type 2 diabetics. He had favorable initial impressions of the drug. Collectively, the feedback suggested that Afrezza could be a desirable option as a first insulin or an alternative to injectable mealtime insulin, but that it will likely take additional time to educate physicians to use Afrezza to its full potential. As a result, Deepak now expects an Afrezza “trajectory” of ten years, resulting in his price target coming down to $9 from $10.
|
|
|
Post by jpg on Apr 9, 2015 13:28:32 GMT -5
Duplicate posting erased
|
|